Business ❯ Pharmaceutical Industry

Acquisitions

Bristol Myers Squibb Foreign Investment Sanofi Johnson & Johnson J.P. Morgan Healthcare Conference Financial Outlook Intra-Cellular Therapies

Ianalumab Plus Eltrombopag Extends Disease Control in Phase 3 ITP Study Published in NEJM

Peer‑reviewed results point to a finite, disease‑modifying strategy for previously treated patients, with regulatory decisions still ahead.

FDA Approves J&J’s Caplyta for Major Depressive Disorder

Sanofi’s Efdoralprin Alfa Shows Superior Biomarker Response to Plasma Therapy in Phase 2 AATD Trial